Podcasts about dmd

Functional dentistry is emerging as a powerful missing link in systems-based care. In this episode of New Frontiers in Functional Medicine, Dr. Kara Fitzgerald sits down with Staci Whitman, DMD, IFMCP, a leading voice in functional pediatric dentistry and co-founder of the upcoming Institute for Functional Dentistry. Together, they explore how the oral microbiome, airway health, saliva, hormones, nutrition, and stress physiology shape systemic inflammation, chronic disease risk, and long-term health outcomes. You'll learn how to recognize oral contributors to gut issues, autoimmunity, cardiometabolic disease, cognitive decline, sleep disorders, and more—plus practical tools you can use right away in a medical setting, including a simple five-question airway and breathing screener. If you're looking to expand your longevity and whole-body health framework, this conversation offers clear, actionable insights you won't want to miss. Full show notes + references: https://www.drkarafitzgerald.com/fxmed-podcast/ GUEST DETAILS Dr. Staci Whitman is a board-certified pediatric and functional dentist and co-founder of the Institute for Functional Dentistry (IFD). She integrates the oral microbiome, airway and sleep health, nutrition, hormones, and early childhood development into modern dental care. She also founded Bloom Kids Dentistry and has an upcoming book on the oral microbiome. Website: http://doctorstaci.com THANKS TO OUR SPONSORS DIAMOND DUTCH: https://dutchtest.com/for-providers Biotics Research: https://bit.ly/2IHK6Xd GOLD TimeLine Nutrition: https://tinyurl.com/bdzx2xms Vibrant Wellness: https://www.vibrant-wellness.com/ EXCLUSIVE OFFERS FROM OUR SPONSORS OneSkin: Get 15% off OneSkin with the code DRKARA at http://oneskin.co/DRKARA Find out why MitoQ's mitochondria-targeting is a critical step for your healthspan and longevity strategy. http://mitoq.com/drkara *CONNECT with DrKF* Want more? Join our newsletter here: https://www.drkarafitzgerald.com/newsletter/ Or take our pop quiz and test your BioAge! https://www.drkarafitzgerald.com/bioagequiz YouTube: https://tinyurl.com/hjpc8daz Instagram: https://www.instagram.com/drkarafitzgerald/ Facebook: https://www.facebook.com/DrKaraFitzgerald/ DrKF Clinic: Patient consults with DrKF physicians including Younger You Concierge: https://tinyurl.com/yx4fjhkb Younger You Practitioner Training Program: www.drkarafitzgerald.com/trainingyyi/ Younger You book: https://tinyurl.com/mr4d9tym Better Broths and Healing Tonics book: https://tinyurl.com/3644mrfw

On this week's episode, Grace Colón, Chris Garabedian, Sam Fazeli, Paul Matteis, Yaron Werber, and special guest John Stanford kick off with a policy discussion on the National Defense Authorization Act (NDAA), outlining both the opportunities and constraints it presents for biotech. The bill includes major biotech provisions such as a scaled back-down version of the BIOSECURE Act and the creation of a DoD Biotech Office, which suggests that biotech is now viewed as a national security asset. The conversation then shifts to positive signs in the biotech sector, including rising valuations, a decrease in companies with negative enterprise value, and predictions for the number of IPOs expected in the first half of 2026. Next, the group discusses conference highlights, including data from ASH presented by Lilly, BeOne Medicines, Gilead, and Arcellx versus J&J and Legend, as well as Genmab's Epkinly. In other data news, the discussion turns to Dyne Therapeutics' plans to seek FDA approval for DYNE-251 for DMD, following promising Phase 1/2 trial results. Despite some investor concerns about the FDA's regulatory stance on rare diseases, sentiment remains optimistic that it will be approved. The episode closes with a round robin where each co-host shares their optimism levels for biotech in 2026, rating it on a scale from 1 to 10. *This episode aired on December 12, 2025.

Untying the Knot: Exploring Adult Tongue Ties with Lauren Kight, DMD In this captivating episode of The Headache Doctor Podcast, Dr. Taves sits down for an enlightening conversation with Lauren Kight, DMD, a Myofunctional Therapist, to delve into the fascinating world of adult tongue ties. Lauren shares her unique journey from dental school to becoming a Myofunctional Therapist, shedding light on her personal struggle with discovering a tongue tie as an adult.Through personal anecdotes and professional expertise, Lauren offers a comprehensive understanding of the role of myofunctional therapy in addressing tongue ties and associated symptoms. Dr. Taves and Lauren explore the importance of early detection and intervention, emphasizing the potential benefits for patients seeking relief from chronic headaches and migraines. If you'd like to learn more about Lauren, check out: https://mywholemouthhealth.com Novera: Headache Center

Untying the Knot: Exploring Adult Tongue Ties with Lauren Kight, DMD In this captivating episode of The Headache Doctor Podcast, Dr. Taves sits down for an enlightening conversation with Lauren Kight, DMD, a Myofunctional Therapist, to delve into the fascinating world of adult tongue ties. Lauren shares her unique journey from dental school to becoming a Myofunctional Therapist, shedding light on her personal struggle with discovering a tongue tie as an adult.Through personal anecdotes and professional expertise, Lauren offers a comprehensive understanding of the role of myofunctional therapy in addressing tongue ties and associated symptoms. Dr. Taves and Lauren explore the importance of early detection and intervention, emphasizing the potential benefits for patients seeking relief from chronic headaches and migraines. If you'd like to learn more about Lauren, check out: https://mywholemouthhealth.com Novera: Headache Center

On this week's episode, Josh Schimmer, Brian Skorney, Paul Matteis, and Graig Suvannavejh share their outlook for the biotech industry in 2026, including a lively discussion on IPO market and predictions for what to expect next year. The discussion then shifts to Washington, where Tracy Beth Høeg has been appointed acting CDER director -- the fifth person to lead CDER this year -- following Richard Pazdur's sudden retirement and ongoing staffing volatility at the agency. Next the co-hosts mention the FDA's moves to speed up drug approvals, the plausible mechanism pathway, and latest with vaccine policies. The FDA's final minutes from a pre-BLA meeting with UniQure and the implications for the broader gene therapy landscape are also discussed. Capricor's positive DMD cell therapy results are also highlighted, reviving hopes for FDA approval. The conversation shifts to data news, including BMS' update on the ADEPT-2 study readout for Cobenfy in Alzheimer's disease psychosis, which the co-hosts read as a net positive. Praxis Medicine's positive Phase 2 results for its seizure drug and ongoing FDA discussions, and Janux Therapeutics in prostate cancer. Otsuka pricing Voyxact at $390K a year is briefly mentioned. The episode concludes with excitement for upcoming conferences including ASH and JPM. *This episode aired on December 5, 2025. 

Dystrophinopathies are heritable muscle disorders caused by pathogenic variants in the DMD gene, leading to progressive muscle breakdown, proximal weakness, cardiomyopathy, and respiratory failure. Diagnosis and management are evolving areas of neuromuscular neurology. In this episode, Kait Nevel, MD, speaks with Divya Jayaraman, MD, PhD, an author of the article "Dystrophinopathies" in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Jayaraman is an assistant professor of neurology and pediatrics in the division of child neurology at the Columbia University Irving Medical Center in New York, New York. Additional Resources Read the article: Dystrophinopathies Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @IUneurodocmom Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Nevel: Hello, this is Dr Kate Nevel. Today I'm interviewing Dr Divya Jayaraman about her article on dystrophinopathies, which she wrote with Dr Partha Ghosh. This article appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Divya, welcome to the podcast, and please introduce yourself to the audience. Dr Jayaraman: Thank you so much, Dr Nevel. My name is Divya, and I am an assistant professor of Neurology and Pediatrics at Columbia University Irving Medical Center, and also an attending physician in the Pediatric Neuromuscular program there. In that capacity, I see patients with pediatric neuromuscular disorders and also some general pediatric neurology patients and also do research, primarily clinical research and clinical trials on pediatric neuromuscular disorders. Dr Nevel: Wonderful. Thank you for sharing that background with us. To set us on the same page for our discussion, before we get into some more details of the article, perhaps, could you start with some definitions? What comprises the dystrophinopathies? What are some of the core features? Dr Jayaraman: So, the dystrophinopathies, I like that term because it is a smaller subset from the muscular dystrophies. The dystrophinopathies are a spectrum of clinical phenotypes that are all associated with mutations in the DMD gene on chromosome X. So, that includes DMD---or, Duchenne muscular dystrophy---, Becker muscular dystrophy, intermediate muscular dystrophy (which falls in between the two), dilated cardiomyopathy, asymptomatic hyperCKemia, and manifesting female carriers. In terms of the core features of these conditions, so, there's some variability, weakness being prominent in Duchenne and also Becker. The asymptomatic hyperCKemia, on the other hand, may have minimal symptoms and might be found incidentally by just having a high CK on their labs. They all will have some degree of elevated CK. The dilated cardiomyopathy patients, and also the Becker patients to a lesser degree, will have cardiac involvement out of proportion to skeletal muscle involvement, and then the manifesting carriers likewise can have elevated CK and prominent cardiac involvement as well as some milder weakness. Dr Nevel: Now that we have some definitions, for the practicing neurologists out there, what do you think is the most important takeaway from your article about the dystrophinopathies? Dr Jayaraman: I like this question because it suggests that there's something that, really, any neurologist could do to help us pick up these patients sooner. And the big takeaway I want everyone to get from this is to check the CK, or creatine kinase, level. It's a simple, cheap, easy test that anyone can order, and it really helps us a lot in terms of setting the patient on the diagnostic odyssey. And in terms of whom you should be thinking about checking a CK in, obviously patients who present with some of the classic clinical features of Duchenne muscular dystrophy. This would include young boys who have toe walking, as they're presenting, sign; or motor delayed, delayed walking. They may have calf hypertrophy, which is what we say nowadays. You might have seen calf pseudohypertrophy in your neurology textbooks, but we just say calf hypertrophy now. Or patients can often have a Gowers sign or Gowers maneuver, which is named after a person called Gowers who described this phenomenon where the child will basically turn over and use their hands on the floor to stand up, usually with a wide-based gait, and then they'll sort of march their hands up their legs. That's the sort of classic Gowers maneuver. There are modified versions of that as well. So, if anyone presents with this classic presentation, for sure the best first step is to check a CK. But I would also think about checking a CK for some atypical cases. For example, any boy with any kind of motor or speech delay for whom you might not necessarily be thinking about a muscle disorder, it's always good practice to check a CK. Even a boy with autism for whom you may not get a good clinical exam. This patient might present to a general pediatric neurology clinic. I always check a CK in those patients, and you'll pick up a lot of cases that way. For the adult folks in particular, the adult neurologist, a female patient could show up in your clinic with asymptomatic hyperCKemia. And I think it's an important differential to think about for them because this could have implications not just for their own cardiac risks, but also for their family planning. Dr Nevel: So, tell us a little bit more about the timing of diagnosis. Biggest takeaway: check a CK if this is anywhere on your radar, even if somewhat of an atypical case. Why is it so important to get kiddos started on that diagnostic odyssey, as you called it, early? Dr Jayaraman: This is especially important for kids because if they especially get a Duchenne muscular dystrophy diagnosis, you might be making them eligible for treatments that we've had for some time, and also treatments that were not available earlier that hinge on making that diagnosis. So, for example, people may be skeptical about steroids, but there's population data to suggest that initiation and implementation of steroids could delay the onset of loss of ambulation as much as three years. So, you don't want to deprive patients of the chance to get that. And then all the newer emerging therapies---which we'll be talking about later, I'm sure---require a Duchenne muscular dystrophy diagnosis. So, that's why it's so important to check a CK, have this on your radar, and then get them to a good specialist. Dr Nevel: I know that you alluded already, or shared a few of the kind of exam paroles or findings among patients with dystrophinopathy. But could you share with us a little bit more how you approach these patients in the clinic who are presenting with muscle weakness, perhaps? And how do you approach this or think about this in terms of ways to potentially differentiate between a dystrophinopathy versus another cause of motor weakness or delay? Dr Jayaraman: It's helpful to think through the neuraxis and what kinds of disorders can present along that neuraxis. A major differential that I'm always thinking about when I'm seeing a child with proximal weakness is spinal muscular atrophy, which is a genetic anterior horn cell disorder that can also present in this age group. And some of the key differences there would be things like reflexes. So, you should have dropped reflexes in spinal muscular atrophy. In DMD, surprisingly, they might have preserved Achilles reflexes even if their patellar reflexes are lost. It may only be much later that they go on to lose their Achilles reflex. So, if you can get an Achilles reflex, that's quite reassuring, and if you cannot, then you need to be thinking about spinal muscular atrophy. They can both have low muscle tone and can present quite similarly, including with proximal weakness, and can even have neck flexion weakness. So, this is an important distinction to make. The reason for that is, obviously there are treatments for both conditions, but for spinal muscular atrophy, timing is very, very important. Time is motor neurons, so the sooner you make that diagnosis the better. Other considerations would be the congenital muscular dystrophies. So, for those that they tend to present a lot younger, like in infancy or very early on, and they can have much, much higher CKS in that age range than a comparable Duchenne or Becker muscular dystrophy patient. They can also have other involvement of the central nervous system that you wouldn't see in the dystrophinopathies, for example. My mnemonic for the congenital muscular dystrophies is muscle-eye-brain disease, which is one of the subtypes. So, you think about muscle involvement, eye involvement, and brain involvement. So, they need an ophthalmology valve. They can have brain malformations, which you typically don't see in the dystrophinopathies. I think those are some of the major considerations that I have. Obviously, it's always good to think about the rest of the neuraxis as well. Like, could this be a central nervous system process? Do they have upper motor neuron signs? But that's just using all of your exam tools as a neurologist. Dr Nevel: Yeah, absolutely. So, let's say you have a patient in clinic and you suspect they may have a dystrophinopathy. What is your next diagnostic step after your exam? Maybe you have an elevated CK and you've met with the patient. What comes next? Dr Jayaraman: Great question. So, after the CK, my next step is to go to genetics. And this is a bit of a change in practice over time. In the past we would go from the CK to the muscle biopsy before genetic testing was standard. And I think now, especially in kids, we want to try and spare them invasive procedures where possible. So, genetic testing would be the next step. There are a few no-charge, sponsored testing programs for the dystrophinopathies and also for some of the differential diagnosis that I mentioned. And I think we'll be including links to websites for all of these in the final version of the published article. So, those are a good starting point for a genetic workup. It's really important to know that, you know, deletions and duplications are a very common type of mutation in the DMD gene. And so, if you just do a very broad testing, like whole exome, you might miss some of those duplications and deletions. And it's important to include both checking for duplications and deletions, and also making sure that the DMD gene is sequenced. So always look at whatever genetic test you're ordering and making sure that it's actually going to do what you want it to do. After genetics, I think that the sort of natural question is, what if things are not clear after the genetics for some reason? We still use biopsy in this day and age, but we save it for those cases where it's not entirely clear or maybe the phenotype is a little bit discordant from the genotype. So, for mutations that disrupt the reading frame, those tend to cause Duchenne muscular dystrophy, whereas mutations that preserve the reading frame tend to cause Becker muscular dystrophy. There are some important exceptions to this, which is where muscle biopsy can be especially helpful in sorting it out. So, for example, there are some early mutations early in the DMD gene where, basically, they find an alternate start codon or an initiation codon to continue with transcription and translation. So, you end up forming a largely functional, somewhat truncated protein that gives you more of a milder Becker phenotype. On the other hand, you can have some non-frameshift or inframe mutations that preserve the reading frame, but because they disrupt a very key domain in the protein that's really crucial for its function, you can actually end up with a much more severe Duchennelike phenotype. So, for these sorts of cases, you might know a priori you're dealing with them, but might just be a child who is who you think has DMD has a mutation that's showed up on testing. There isn't enough in the literature to point you one way or another, but they look maybe a little milder than you would expect. That would be a good kid to do a biopsy in because there are treatment decisions that hinge on this. There are treatments that are only for Duchenne that someone with a milder phenotype would not be eligible for. Dr Nevel: So, that kind of stepwise approach, but maybe not all kids need a muscle biopsy is what I'm hearing from you. If it's a mutation that's been well-described in the literature to be fitting with Duchenne, for example. Dr Jayaraman: Absolutely. Dr Nevel: So, after you confirm the diagnosis through genetic testing---and let's say, you know, whether or not you do a muscle biopsy or not, after you know the diagnosis is a dystrophinopathy---how do you counsel the families and your patients? What are the most important points to relay to families, especially in that initial phase where the diagnosis is being made? Dr Jayaraman: This is a lot of what we do in pediatric neurology in general, right? So, I actually picked up this approach from the pediatric hematology oncology specialists at Boston Children's. They had this concept of a day-zero conversation, which is the day that you disclose the life-changing diagnosis or potentially, at some point, terminal diagnosis to a family. And some of the key components of that are a not beating around the bush, telling them what the diagnosis is, and then letting them have whatever emotional response they're going to have in the moment. And you may not get much further than that, but honestly, you want them to take away, this is what my child has. I did not do anything to cause this, nor could I have done anything to prevent this. Because often for these genetic conditions, there's a lot of guilt, a lot of parental guilt. So, you want to try and assuage that as much as possible. And then to know that they're not going to be alone on this journey; that, you know, they don't have to have it all figured out right then, but we can always come back and answer any questions they have. There's going to be a whole team of specialists. We're going to help the family and the kid manage this condition. Those are sort of my big takeaways that I want them to get. Dr Nevel: Right. And that segues into my next question, which is, who is part of that team? I know that these teams that help take care of people with dystrophinopathies and other muscle disorders can be very large teams that span multiple specialists. Can you talk a little bit more about that for this group of patients? Dr Jayaraman: Of course. So, the neuromuscular neurologist, really, our role is in coordinating the diagnosis, the initiation of any disease-specific treatments, and coordinating care with a whole group of specialists. So, we're sort of at the center of that, but everyone else is equally important. So, the other specialists include physical therapists; occupational therapists; rehab doctors or physiatrists; orthotists who help with all of the many braces and other devices that they might need, wheelchairs; pulmonology, of course, for managing the respiratory manifestations of this. It becomes increasingly important over time, and they are involved early on to help monitor for impending respiratory problems. Cardiac manifestations, this is huge and something that you should be thinking about even for your female carriers, the mother of the patient you're seeing in the clinic, or your patient who comes to adult clinic with asymptomatic hyperCKemia. if you end up making a diagnosis of DMD carrier for those patients, or if you make a Becker diagnosis, the cardiac surveillance is even more important because the cardiac involvement can be out of proportion to the skeletal muscle weakness. And of course, extremely important for the Duchenne patients as well. Endocrinologists are hugely important because in the course of treating patients with steroids, we end up giving them a lot of iatrogenic endocrinologic complications. Like they might have delayed puberty, they might have loss of growth, of height; and of course metabolic syndrome. So, endocrinology is hugely important. They're also important in managing things like fracture prevention, osteoporosis, prescribing bisphosphonates if necessary. Nutrition and GI are also important, not just later on when they might need assistance to take in nutrition, whether that's through tube feeds, but also earlier on when we're trying to manage the weight. Orthopedics, of course, for the various orthopedic complications that patients develop. And then finally, a word must be said for social work and behavioral and mental health specialists, because a lot of this patient population has a lot of mental health challenges as well. Dr Nevel: After you give the diagnosis, you've counseled the patient and families and you've had those kind of initial phase discussions, the day-zero discussion, when you start getting into discussions or thoughts about management, disease-specific medication. But what are the main categories of the treatment options, and maybe how do you kind of approach deciding between treatment options for your patients? Dr Jayaraman: So, there are two broad categories that I like to think about. So, one is the oral corticosteroids and oral histone deacetylase, or HDAC inhibitors, which share the common characteristic that they are non-mutation specific. And within corticosteroids, patients now have a choice between just Prednisone or Prednisolone, or Deflazacort or Vermilion. The oral HDAC inhibitors are newly FDA-approved as a nonsteroidal therapy in addition to corticosteroids in DMD patients above six years of age. I would say we're in the early phase of adoption of this in clinical practice. And then the other big category of treatment options would be the genetic therapies as a broad bucket, and this would include gene therapy or gene replacement therapy, of which the most famous is the microdystrophin gene therapy that was FDA-approved first on an accelerated approval basis for ages four to eight, and then a full approval in that age group as well as an accelerated approval for all comers, essentially, with DMD. This is obviously controversial. Different centers approach this a bit differently. I think our practice at our site has been to focus on the ambulatory population, just thinking about risk versus benefit, because the risks are not insignificant. So really this is something that should be done by experienced sites that have the bandwidth and the wherewithal to counsel patients through all of this and to manage complications as they arise with regular monitoring. And then another class that falls within this broader category would be the Exon-skipping therapies. So as the name suggests, they are oligonucleotides that cause an Exon to be skipped. The idea is, if there is a mutation in a particular Exon that causes a frame shift, and there's an adjacent Exon that you can force skipping of, then the resulting protein, when you splice the two ends together, will actually allow restoration of the reading frame. I think the picture I want to paint is that there's a wide range of options that we present to families, not all of which everyone will be eligible for. And they all have different risk profiles. And I really think the choice of a particular therapy has to be a risk-benefit decision and a shared decision-making process between the physician and the family. Dr Nevel: What is going on in research in this area? And what do you think will be the next big breakthrough? I know before we started the recording you had mentioned that there's a lot of things going on that are exciting. And so, I'm looking forward to hearing more. Dr Jayaraman: Of course. So, I'll be as quick as I can with this. But I mentioned that next-generation Exon skipping therapies, I think the hope is that they will be better at delivering the Exon skipping to the target tissue and cells and that they might be more efficacious. I'm also excited about next-generation gene therapies that might target muscle more specifically and hopefully reduce the off-target effects, or combination use of gene therapies with other immunosuppressive regimens to improve the safety profile and maybe someday allow redosing, which we cannot do currently. Or potentially targeting the satellite cells, which are the muscle stem cells, again, to improve the long term durability of these genetic therapies. Dr Nevel: That's great, thank you for sharing. Thank you so much for talking to me today about your article. I really enjoyed learning more about the dystrophinopathies. Today I've been interviewing Dr Divya Jayaraman about her article on the dystrophinopathies, which she wrote with Dr Partha Ghosh. This article appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Please be sure to check out the Continuum Audio episodes from this and other issues. Also, please read the Continuum articles for more details than what we were able to get to today during our discussion. Thank you, as always, so much to the listeners for joining us today, and thank you, Divya, for sharing all of your knowledge with us today. Dr Jayaraman: Thank you so much for having me on the podcast. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

This week, the Dental Amigos welcome Sharon Bleiler, DMD, practicing dentist and co-founder of Team Care Dental, and her husband Colin Ambler, MBA, business strategist and software architect behind the platform. Together, they transformed their 14-chair practice in Jenkintown, Pennsylvania into a model of team-driven growth and innovation. In this episode, Sharon and Colin share their journey from building a start-up dental practice to launching Team Care Dental, a platform that empowers staff through real-time incentives, performance tracking, and culture-building tools that drive profitability and engagement. To learn more about Sharon, Colin, and Team Care Dental, visit www.teamcaredental.com. Listeners who want to reach Paul can do so at Paul@DentalNachos.com and those who want to reach Rob can do so at Rob@RMontgomery-law.com.

Muscular dystrophy (MD) is a group of genetic diseases that affect about 16 to 25 per 100,000 people in the US, with the most common childhood form being Duchenne muscular dystrophy (DMD) and the most common adult form being myotonic dystrophy. The prevalence of DMD is estimated at around 1 in 3,500 live male births. Prenatal carrier screening for this is part of the ACMG Tier 3 expanded carrier panel. This is different from spinal muscular atrophy (SMA). As we recently had a patient who was a MD carrier, with affected male children, who we cared for, we decided to do a quick review of muscular dystrophy: its prevalence, genetics, and evaluation of asymptomatic maternal carriers.1. https://www.mda.org/disease/duchenne-muscular-dystrophy/causes-inheritance2.https://www.nichd.nih.gov/health/topics/musculardys/conditioninfo/causes3. https://www.nhs.uk/conditions/muscular-dystrophy/4. ACMG: https://thednaexchange.com/2022/03/30/acmg-carrier-screening-guideline-the-hypothetical-tier-3-panel/#:~:text=The%20goal%20of%20this%20ACMG,1%20in%2040%2C000%20or%20higher.

Tonmya now available for fibromyalgia; safety warnings for DMD treatment; mitapivat shows mixed results in sickle cell disease trial; Redemplo approved for familial chylomicronemia syndrome; Hyrnuo approved for HER2-mutant NSCLC.

Musculoskeletal disorders (MSDs) affect up to 96% of dental hygienists, leading to pain, fatigue, and lost income. Learn how adaptive curette designs reduce pinch force, muscle strain, and discomfort—helping clinicians protect their health while maintaining efficiency. Petra Wilder-Smith, DDS, DMD, PhD Read by Jackie Sanders  https://www.rdhmag.com/ergonomics/instruments-handpieces/article/55310267/dental-ergonomics-and-instrument-design-how-adaptive-curettes-reduce-muscle-strain-and-improve-clinician-comfort

Dallas Davidson is the founder of DMD Marketing and a member of the Board of Destination Scenic Rim. Growing up on a sheep dairy farm in Queensland herself, she now helps farmers and producers share their day to day with the broader audience through their integration of marketing with farm life. In this episode, Dallas shares her path towards where she is now and how she ended up loving lending farmers a creative hand. Dallas explains DMD marketing and how they help producers present their stories and businesses. She talks about the role Destination Scenic Rim plays in promoting agritourism in the area. Finally, she touches on the struggle of keeping farms within the family and how farmers should be having the hard conversations with the next generation. Resources and links: DMD Marketing Website Destination Scenic Rim Website Dallas Davidson on Linkedin Send us your story: Do you know someone (or are you someone) who’d make a great potential guest on a future episode of Beyond the Farm Gate? Drop us a line at beyondthefarmgate@bendigobank.com.au. Connect: Bendigo Bank Agribusiness website Bendigo Bank on Facebook Bendigo Bank on X Bendigo Bank on LinkedIn Bendigo Bank on YouTube In this podcast any opinions, estimates and projections are for informational purposes only and any advice provided is of a general nature only and does not take into account your personal needs, objectives and financial circumstances. You should consider whether it is appropriate for your situation.See omnystudio.com/listener for privacy information.

In this episode, Hallie Bulkin welcomes special guest Dr. Anita Gouri, a board-certified pediatric dentist, to dive deep into the critical, often-missed connection between pediatric dentistry and a child's overall airway health and development.Dr. Gouri shares her personal journey into airway and tissue-focused dentistry, motivated by her own daughter's and nephew's feeding and developmental challenges due to undiagnosed tongue ties. They emphasize the absolute necessity of a multidisciplinary approach, stressing that therapy (SLP, OT, IBCLC, etc.) is optimal before and after a tongue tie release for the best outcomes and to avoid reattachment or unresolved symptoms. The conversation extends to older children, discussing the importance of an airway evaluation before prescribing ADHD medications and the dramatic life-changing results of early palatal expansion to open the airway.In this episode, you'll learn:✔️ Dr. Gouri's personal experience discovering her daughter's tongue tie at age 7, long after dealing with feeding issues, colic, and difficulty eating non-pureed foods. ✔️ Why pre- and post-operative therapy (like with an SLP, OT, or IBCLC) is 100% crucial for optimal outcomes following a tongue tie release. ✔️ The importance of getting an airway evaluation before putting children on ADHD medication. ✔️ Key signs of pediatric airway issues during sleep, including mouth breathing , tossing/turning/restless sleep , and the often-missed red flag of hyperextension of the neck. ✔️ The dramatic benefits of early palatal expansion (as early as 3 or 4 years old) to open the airway, often resolving issues like chronic infections (like croup) and snoring , even if the child does not have a crossbite. ✔️ How simple strategies like sleep hygiene (removing dust mite harbingers like stuffed animals and blankets) and dietary changes (like kicking gluten) can reduce inflammation and improve breathing. ✔️ Why a "quick snip" of a tongue tie may not address the entire posterior tie, which can lead to later issues like speech problems.RELATED EPISODES YOU MIGHT LOVEEp 219: Rapid Palatal Expansion for Airway Clearance and Mia's Airway JourneyEp 333: Transforming airway health & smiles with MARPE featuring Dr. Svitlana Koval, DMD, MSc, BDSOTHER WAYS TO CONNECT & LEARN

Our guest today is Dr. Yan Kalika, DMD, MS, a certified specialist in orthodontics and dentofacial orthopedics. He earned his dental degree with honors from Harvard School of Dental Medicine and completed his orthodontic training — along with a master's degree in oral biology — at the University of California, San Francisco. We'll be talking with him about how he leverages ClearCorrect, AI, and digital workflows to attract new patients, streamline operations, and grow a profitable practice — all while keeping patients at the center of care.

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW's Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week's leading story came from a positive development in biopharma, with top companies reporting market growth in Q3 of 2025. Elsewhere, new research could help combat yellow fever and weight loss, while £500,000 was awarded to a biotech company to develop a DMD therapy.  You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In this episode, Hallie Bulkin dives into a topic we all need to hear as we navigate Thanksgiving, Christmas, and the rest of the holiday season: how our festive food and drink habits directly impact our sleep and breathing.It's about more than just your waistline, what you eat and drink this time of year directly affects your airway health and daily function. Hallie connects the dots between common holiday culprits like sugar and alcohol, and poor sleep quality, snoring, and overall well-being. She emphasizes the importance of moderation, modeling good habits for your kids, and creating simple strategies to thrive through the season.In this episode, you'll learn: ✔️Why sugar contributes to inflammation throughout the body, which can cause swelling and restrict an already tight airway. ✔️How consuming too much sugar can lead to sleep-disordered breathing, disrupted sleep, and snoring. ✔️The signs of sugar impact in children (hyperness followed by a hard crash, restless sleep) and adults (frequent nighttime waking, morning exhaustion, or a "low-level cloud" feeling). ✔️Why alcohol acts as a muscle relaxer, which can cause airway muscles to be more easily collapsible, leading to more snoring and potentially more apnic events. ✔️The benefit of balancing carbohydrates (sugar) with protein, fiber, and fat to help your body process food with greater ease. ✔️Simple strategies for both adults and families to focus on airway health during the holidays.RELATED EPISODES YOU MIGHT LOVEEp 332: The Interconnectedness of Oral and Systemic Health with Amber White RDH, HHPEp 333: Transforming airway health & smiles with MARPE featuring Dr. Svitlana Koval, DMD, MSc, BDSOTHER WAYS TO CONNECT & LEARN

On this week's episode, Graig Suvannavejh, Paul Matteis, Brian Skorney, Yaron Werber, Chris Garabedian, and guest Adam Feuerstein open with a discussion on George Tidmarsh's departure from the FDA and the uncertainty it has caused in the markets. Next, the co-hosts discuss the shifting policies of the FDA and Sarepta's Phase 3 ESSENCE trial of casimersen for DMD with the group debating if the drug actually works. Biohaven's complete response letter for its new drug application for its spinocerebellar ataxia drug is also mentioned. The co-hosts also overviewed the FDA's decision deeming Uniqure's Huntington's disease therapy data inadequate, and the read through for other companies like Stoke Therapeutics. The conversation shifts to company news where Novo Nordisk and Pfizer's bidding war for Metsera is noted as a positive for biotech investors. Next the co-hosts discuss Soleno Therapeutic's stock moves amid questions about its growth trajectory. The episode concludes with a look ahead to ASH 2025 with a preview of Terns Pharmaceuticals CML data. *This episode aired on November 7, 2025. 

From playground falls to sports injuries, oral trauma is part of growing up. But when a tooth gets chipped, knocked out or a lip is cut, it can be stressful for families and challenging for providers. In this episode, we take a closer look at pediatric dental and oral trauma from the primary care perspective. We are focusing on what to look for, when to act and how to guide families through those anxious first moments after an injury. This episode was recorded on the exhibit floor at the 2025 American Academy of Pediatrics Conference in Denver, Colorado. Joining us is Erica Brecher, DMD. She is a pediatric dentist with Duke Street Pediatric Dentistry and is on staff at Duke Children's Hospital. She is also an adjunct professor at the University of North Carolina School of Dentistry. Some highlights from this episode include:  Most common oral and dental traumas in kids  How outcomes differ from baby teeth to permanent teeth  What steps a pediatrician can take to save a tooth  Why a strong partnership between the pediatric and dental home can improve outcomes    For more information on Children's Colorado, visit: childrenscolorado.org. 

15 Mariner fans' cars were towed during game 6 of ALCS, which was quite upsetting for them. Find out what went wrong on the DMD.

The FDA made waves in early September when it announced a plan to publicly release complete response letters (CRLs) at the same time they are issued to sponsoring companies, part of what the agency calls a push toward “radical transparency.” At the same time, the FDA released 89 new CRLs, adding to the more than 200 that were previously made public in July and shedding more light on the agency’s often opaque review process. That earlier document dump, though, only included rejection letters for drugs that were eventually approved. Now, for the first time, the agency is releasing CRLs for unapproved drug candidates—including recent high-profile rejections such as Ultragenyx’s gene therapy for Sanfilippo syndrome type A, Capricor Therapeutics’ Duchenne muscular dystrophy cell therapy and Replimune’s melanoma drug. Publicly airing the rationale for rejecting drug candidates is a significant shift for the FDA and a potential cause for concern for the biopharma industry. To unpack what the new policy means for drug developers, Fierce Biotech’s Darren Incorvaia sat down with Torrey Cope, a lawyer with Sidley Austin who represents and advises life sciences companies on issues related to the FDA. To learn more about the topics in this episode: FDA releases ‘initial batch’ of more than 200 drug rejection letters FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub FDA misinterpreted efficacy data that prompted DMD rejection, Capricor claims ‘Weak’ evidence and an ‘unpleasant’ odor: FDA sheds light on drug refusal process 'Several concerning observations': FDA sheds more light on reasons it rejected drugs See omnystudio.com/listener for privacy information.

  Implementing Zero Trust in a complex federal environment includes protecting data. To reach this goal, CISA has updated its recommendations for Continuous Diagnostics and Mitigation program called the Data Model Document (DMD). It provides the audience with a mechanism to focus on the most recent relevant changes without having to review the document in its entirety.   Today, we sat down with three experts to unpack some of the expanded concepts.   The first challenge is understanding the variety of systems. For example,  Daniel Ane from the TSA shared that they had to report data from eighty different systems. The only time efficient way to collect this varying data is with specific tools.   There is also a matter of control. Mark Hadley from the PNL shares that much critical infrastructure is  owned by the private sector, which can limit what kind of data can be collected.   Finally, Brian Meyer from Axonius makes a practical observation. Let us say you have a set of tools that accomplish the job of accurate data collection. If one gets updated, it can throw the entire compliance process out the window.   It seems obvious that adhering to the strictures of the Data Model Management recommendations will assist in a move to Zero Trust, but administering DMD needs guidance and a data strategy that is practical.    

EP 342: The MARPE Experience – Bodywork, Diet, and the Mind-Body Connection in OrthodonticsIn this engaging conversation, Hallie Bulkin and Jeannie Nelson discuss their upcoming Marpe procedures, sharing their personal experiences, expectations, and the challenges they anticipate. They delve into the intricacies of the Marpe process, the importance of bodywork and therapy, dietary considerations post-procedure, and the psychological aspects of pain management. The discussion also touches on the impact of hormonal changes on pain perception, the significance of airway health, and the aesthetic changes they hope to achieve. Throughout the conversation, they emphasize the journey of orthodontics as a holistic process that goes beyond just physical changes, highlighting the interconnectedness of body, mind, and health.In this episode, you'll learn:✔️Both hosts are undergoing Marpe procedures within 24 hours of each other.✔️The Marpe procedure involves local anesthesia and is not a surgical procedure.✔️Personal goals for the procedure include improved airway health and aesthetics.✔️Orthodontics is more than just straightening teeth; it involves overall health.✔️Bodywork and therapy play a crucial role in the orthodontic journey.✔️Dietary changes will be necessary post-procedure to accommodate healing.✔️Pain management strategies are important for both hosts as they prepare for their procedures.✔️The journey of orthodontics is a holistic process that requires patience and understanding. RELATED EPISODES YOU MIGHT LOVEEp 331: Inside My MARPE Journey with Hallie Bulkin, MA, CCC-SLP, CMT®, CPFT™Ep 333: Transforming airway health & smiles with MARPE featuring Dr. Svitlana Koval, DMD, MSc, BDSOTHER WAYS TO CONNECT & LEARNVisit : https://www.breatheeatsleeptalk.com/

The DMD is here on a Friday! Let's get going!

The DMD is here! And we are ready to chat MARINERS TURNSTILE AND SO MUCH MORE!

Happy Birthday Migs! Plus the DMD is here and we chat with Seahawks' Abe Lucas!

Want to Support the Show? Visit Our Patreon at or pick up a tee shirt at Silverball Swag  Check out Flip N Out Pinball for all your pinball needs! Topic begins at 12:28   Episode Summary:   Pinball has had a dramatic change since the end of the modern DMD era at Stern. The designers we all know and love from the 80s and 90s have begun to retire, slow down, or leave the industry. A new wave of designers has started to slide in and learn from the masters… The first major new designer to come along was the tournament player Keith Elwin.   Some say Keith Elwin is the second coming of our lord and saviour Steve Ritchie. Others say ‘in Elwin we trust'… but is that all hype? Has Keith Elwin changed the pinball designer game as much as some believe?   Join us this month as we chat about the second coming golden age of pinball, Keith's dominance of tournament pinball, his deep understanding of repair, play, code, and design, his first pin, and his second smash hit follow-up!   Sources: Kineticist Keith Elwin Profile Head2Head Pinball Podcast Ep. 45 - Iron Maiden Head2Head Pinball Podcast Ep. 106 - Jurassic Park Just Another Pinball Podcast - Godzilla  Flip N Out Podcast with Joel E - Jaws Loser Kid Podcast - King Kong Pinside Keith Elwin Designer Profile

Ever wonder what really goes on in the minds of dentists considering a major practice overhaul? In this episode, your hosts pull back the curtain on the emotional journey they witness at their events. They share observations ranging from initial skepticism and hesitation to genuine gratitude and excitement as attendees realize the potential of the firm's services.We dive deep into why being coachable, vulnerable, and self-aware isn't just a soft skill—it's the single most important factor for dentists looking to unlock their practices' profitability and long-term viability. Listen in to learn what it takes to stop resisting change and start building the practice of your dreams.Interested in more info on how to: Earn More, Save More, and Retire EarlyUpcoming Tour Dates: Go to our EVENTS page for infoFacebook: Four Quadrants AdvisoryInstagram: @fourquadrantsadvisoryLinkedIn: Four Quadrants Advisory

Happy Tuesday the DMD is here! Let's chat about that COSTCO Executive status!

The DMD is here! Let's chat Savannah Bananas!

“I want people to look at their toothpaste just like they look at their food labels,” says Staci Whitman, DMD.  Staci Whitman, DMD, board-certified pediatric dentist and a leader in functional dentistry, joins us today to share science-backed insights on how your oral health influences your whole-body health, and the simple steps you can take to optimize it:  - Oral health is the cornerstone of longevity (~3:00)  - Oral health & cognitive function (~4:30) - Testing (6:00) - Symptoms of oral dysbiosis (~10:00) - Nutrition for oral care (~12:00) - The importance of nasal breathing (~14:30) - Flossing & water picks (~15:00) - The impact of ultra-processed foods (~16:00) - Her daily routine (~17:00) - How to find the best products (~21:00) - The truth about fluoride (~25:00) - What is dental fluorosis? (~30:00) - Hydroxyapatite &  theobromine (~31:00) - Her oral healthcare line, Fygg (~33:00) - The case against mouthwash (~34:45) - How to drink coffee to protect your teeth (~37:00) - How to whiten your teeth (~38:00) - The risks of veneers (~42:30) - Root canal experiences (~43:15) - The Institute of Functional Dentistry (~52:00) Referenced in the episode:  - Follow Whitman on Instagram (@doctor_staci & @feedyourgoodguys) - Check out her website (https://doctorstaci.com/)  - Use code MBG20 for 20% off a purchase at fygg.com (one-time and subscription) This episode of the mindbodygreen podcast was created in partnership with MassMutual. MassMutual believes in helping people live well—so they can live more. Learn more at MassMutual.com/Wellness. We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has made a significant move in the pharmaceutical industry by acquiring 89bio for $3.5 billion, with a contingent value right of $6 per share. The acquisition includes pegozafermin, an analog in late-stage development for metabolic dysfunction-associated steatohepatitis. Meanwhile, former CDC director Susan Monarez spoke to the Senate about her firing, alleging that Health Secretary Robert F. Kennedy Jr. accused CDC employees of "killing children." In other news, Roivant and Pfizer's therapy shows promise in a rare inflammatory condition, BMS and Novo Nordisk have announced layoffs in New Jersey, and Sino Biological has developed a high-throughput platform for AI-driven antibody discovery. Additionally, Lexicon has backed phase III decision for a non-opioid pain medication, and Rosnilimab shows promise as a potential next-generation treatment for rheumatoid arthritis. The pharmaceutical industry is navigating uncertainty during turbulent times, with companies like Arsenal and X4 laying off staff to cut costs.The FDA is cracking down on pharmaceutical advertisements in a new regulatory initiative, targeting loopholes in direct-to-consumer ads. Experts believe the FDA is focusing on the wrong issues and should instead address the lack of regulations for compounder drug ads. Akeso, a biotech company in China, has seen success under CEO Michelle Xia's leadership. Other news in the pharmaceutical industry includes the rise of predictive care powered by consumers and AI, ongoing prescriptions of Sarepta's DMD gene therapy despite safety concerns, and companies like Sanofi pulling back from the UK market. Pharma companies are facing challenges in navigating uncertain times amidst layoffs and regulatory crackdowns. Stay tuned for more updates on the latest developments in the industry.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo's amylin analog drug, cagrilintide, has shown a significant 11.8% weight loss in a phase III trial, with improved safety data to address past tolerability issues. The FDA is set to make a decision on the drug, with significant stakes for the company and the Barth Syndrome community. Additionally, Sarepta's DMD gene therapy is still being prescribed by doctors despite safety concerns, and new members have been appointed to the ACIP panel. Stealth Biotherapeutics is awaiting a verdict on their potential treatment for Barth Syndrome, while Sino Biological's high-throughput platform for AI-driven antibody discovery offers promise for advancing therapeutic candidates. Novo and Lilly are competing for market leadership in obesity treatment, while Sanofi and other pharma companies are pulling back from investments in the UK. The pharmaceutical industry is navigating uncertainty during turbulent times.

This week, the Dental Amigos welcome Stephanie Mapp, DMD, dental consultant, speaker, and founder of “Mapp Your Practice.” With over 30 years of clinical and business experience, Dr. Mapp helps dentists navigate PPOs, practice transitions, and sustainable growth strategies. In this episode, Dr. Mapp shares her journey as a multi-practice owner navigating financial and legal adversity. With the knowledge gained from this experience, she now empowers dentists to rethink PPO participation, associate hiring, and practice profitability with clarity and resilience. To learn more about Dr. Mapp and ”Mapp Your Practice,” visit www.mappyourpractice.com. Listeners who want to reach Paul can do so at Paul@DentalNachos.com and those who want to reach Rob can do so at Rob@RMontgomery-law.com.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Capsida has reported a patient death in a gene therapy trial for epilepsy, but the exact cause of death has not been disclosed. The patient had received the gene therapy cap-002. ## The FDA is looking to streamline the development of non-opioid painkillers, while Avidity has seen functional improvements in their DMD therapy. ## The White House is reportedly considering restrictions on Chinese licensing deals in the pharmaceutical industry. ## Lilly is seeking individuals willing to challenge the status quo of medicine. ## Merck has abandoned a $1.3 billion R&D center in London, resulting in layoffs. Novo has cut 9,000 employees, and New York City's life sciences scene is growing. Thank you for tuning in to today's episode of Pharma and Biotech daily. Stay informed and have a great day!

On this episode, hosts Casey Hiers and Jarrod Bridgeman tackle a topic many dentists would rather avoid: the unexpected death of a practice owner. They stress the critical need for proactive financial and estate planning, not just to protect your business but also to spare your loved ones from a complicated and stressful process.Jarrod and Casey emphasize the immense value of having a comprehensive team in place to manage both your personal and professional affairs. They share real-world examples of how their clients' foresight has protected their practices and families, ensuring a smooth transition during an otherwise difficult time. Tune in to learn how to secure your legacy and give your loved ones peace of mind.Interested in more info on how to: Earn More, Save More, and Retire EarlyUpcoming Tour Dates: Go to our EVENTS page for infoFacebook: Four Quadrants AdvisoryInstagram: @fourquadrantsadvisoryLinkedIn: Four Quadrants Advisory

The DMD is here! DAILY MIGS DOWNLOAD! Plus we chat all about the PHILLIES KAREN!

Nick White, DMD, of Lake Mary Pediatric Dentistry, shares insights on dealing with staff shortages and current trends in the dental industry. He discusses taking a hands-on approach to new technology and offers advice for success for emerging leaders in the DSO space.

Nick White, DMD, of Lake Mary Pediatric Dentistry, shares insights on dealing with staff shortages and current trends in the dental industry. He discusses taking a hands-on approach to new technology and offers advice for success for emerging leaders in the DSO space.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne," Barry Byrne, MD, chief medical advisor at the Muscular Dystrophy Association and director of the Powell Gene Therapy Center at the University of Florida, discusses newly published consensus guidelines from the MDA and Parent Project Muscular Dystrophy on the safe delivery and monitoring of gene therapy in Duchenne muscular dystrophy (DMD). Byrne explains the rationale behind convening a global panel of experts, emphasizing the need for standardized practices in patient selection, administration, and follow-up care as gene therapy becomes more widely available. He highlights the importance of expanded multidisciplinary teams—including hematology, cardiology, nephrology, and immunology—in managing immune-related safety concerns, with particular attention to monitoring liver inflammation and emerging strategies such as rapamycin use. In addition, Byrne outlines how these guidelines address real-world challenges around access, including geographic barriers, language considerations, and financial constraints, while underscoring their role in shaping future gene therapy approaches as additional therapies move through development. Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page. Episode Breakdown: 1:00 – Why consensus guidelines were needed for gene therapy in DMD 2:10 – Top-line clinical considerations from the published recommendations 4:30 – Protocols for monitoring and managing adverse events, especially liver toxicity 6:30 – Neurology News Network 8:30 – Addressing health equity, language access, and financial barriers in gene therapy care 12:00 – How these recommendations may shape the future of DMD treatment The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Efgartigimod Aims to Become First Therapy for Seronegative Generalized Myasthenia Gravis Following Positive Phase 3 Data FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease Eisai Submits sBLA for Weekly Subcutaneous Lecanemab as Starting Dose Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Elijah Stacy, founder of Destroy Duchenne, speaks with Kevin Counterman, author of Breakfall, along with Buddy and Alan, about their new book. Breakfall is inspired by Kevin's late brother, Michael, and tells the story of Rudy and the Gallagher family, exploring themes of legacy, resilience, and the impact of Duchenne muscular dystrophy on the whole family.Learn More about Breakfall: https://breakfallbook.comWant to be on the podcast? Click here: https://www.destroyduchenne.org/podca…Learn more about the Destroy Duchenne Podcast here: https://www.destroyduchenne.org/podcastWebsite: https://www.destroyduchenne.orgSocial Media: Facebook:   / destroyduche.  .Instagram:   / destroyduch.  .Twitter: https://twitter.com/destroydisease?la...LinkedIn:   / dest.  .ABOUT DESTROY DUCHENNE PODCAST:A podcast telling the stories of those affected by a fatal muscle-wasting disease, Duchenne muscular dystrophy (DMD), that robs children of their ability to walk by the age of 11, the ability to raise their arms by their teenage years, and eventually their lives in their early 20s.Hosted by 24-year-old founder of the 501(c)3 nonprofit organization Destroy Duchenne, Elijah Stacy, who also suffers from Duchenne muscular dystrophy.The goal of the Destroy Duchenne podcast is very simple, yet ambitious: interview every person that has a relationship to Duchenne—people with Duchenne, parents, family members, friends, teachers, doctors—and tell their story to the world.Destroy Duchenne is a registered 501(c)3 nonprofit organization with the mission: to Complete the Cure for Duchenne muscular dystrophy by advancing medical technologies into human practice.Federal Tax ID: #82-3268952#Breakfall

Host Dr. Joel Berg speaks with Dr. Chelsea Fosse, Vice President of the AAPD Research and Policy Center (RPC) on the current hot topics in public health and how the RPC is working to make an impact. They delve into how pediatric dentistry can continue to lead the way among the other dental specialties and with our medical peers on care for those children and adults with disabilities and other special healthcare needs. Dr. Fosse also shares how AAPD members and other healthcare professionals can turn to the RPC for support with state-specific questions relating to Medicaid or other legislation. Guest Bio: Chelsea Fosse, DMD, MPH is the Vice President, Research & Policy Center at the American Academy of Pediatric Dentistry (AAPD). She is boarded in dental public health. Before shifting her career to work in oral health policy research, she worked as a general dentist treating adults with disabilities. At AAPD, Chelsea leads a team focused on Medicaid policy and program administration, evidence-based dental care, access to high quality and safe dental care, the pediatric dental workforce, and other contemporary issues in oral health, public health, and health policy. She was previously at the American Dental Association (ADA) Health Policy Institute (HPI) where she led policy analysis for issues related to Medicaid and studied the oral health workforce and the industry's response to the COVID-19 pandemic. Before dental school, she worked in the Division of Children with Special Needs at the American Academy of Pediatrics. She currently serves as President of the Board of Directors at Well Child Center, a community-based organization offering WIC, dental, and other social and health services in Elgin, IL. Chelsea received her bachelor's from The University of Texas in 2009, DMD from Rutgers in 2017, and MPH from Columbia University in 2019. She completed a general practice residency at Helen Hayes Hospital in 2018 and a dental public health residency at Jacobi Medical Center in 2020. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The DMD is here! Daly Migs Download! Also we chat about your first job!

The DMD is here! DALY MIGS DOWNLOAD! We also chat with Taryn's hitchhiker!

The DMD is here! Let's get ready and hit this Monday hard! Plus Taryn picked up a hitchhiker?!

The DMD is here! And school is almost started!

Ep 333: Transforming airway health & smiles with MARPE featuring Dr. Svitlana Koval, DMD, MSc, BDSThis week on The Untethered Podcast™, Hallie welcomes back Dr. Svitlana Koval, Florida's leading provider of Miniscrew-Assisted Rapid Palatal Expansion (MARPE). Together, they explore the powerful connection between dental expansion, airway health, and facial balance covering MARPE and clear aligner mechanics, Hallie's personal experience with her children's treatment, timelines, post-care, and the transformative outcomes of a holistic approach.If this episode resonates with you, snap a screenshot of you listening and share it on your Instagram Stories! Tag Hallie @halliebulkin and @drsvitlanakoval to spread the word.In this episode, you'll learn:✔️ Clear Aligner (e.g., Invisalign) Journey and Airway Health✔️ Personal Experience with MARPE and Facial Asymmetry✔️ Understanding MARPE: Procedures and Techniques✔️ Comparing Traditional Expanders and MARPE✔️ Timeline and Procedures for Adult Expansion✔️ Understanding Bone Remodeling and Expansion Techniques✔️ Aesthetic Considerations in Orthodontic Treatment✔️ Timeline for Appliance Removal and Bone Fusion✔️ Impact of Expansion on Facial Structure✔️ Addressing Concerns with Mini Screws and TADs✔️ In-Office Procedure Insights and Patient Care✔️ Managing Asymmetries in Facial StructureRELATED EPISODES YOU MIGHT LOVEEp 263: Breathing Easy – Link Between Orthodontics, Speech & Health with Dr. Svitlana Koval & Tiffany ZilbermanEp 331: Inside My MARPE Journey with yours truly, Hallie BulkinABOUT TODAY'S GUESTI am so excited for you to meet Dr. Svitlana Koval! You can hang out with her over on Instagram and check out her practice at drssk.com.✨ FREE TRAINING ALERT – HAPPENING SEPTEMBER 8–10!If you're an SLP, OT, or student… you need to join me for the FREE 3-Day Pediatric Feeding Screening Training. Over 34,000 of your colleagues have done it — now it's your turn!Here's what you'll get when you sign up:4 hours on a certificate of completion (perfect for your renewal hours)My complete pediatric feeding screening packet — development chart, 50-symptom checklist, findings chart & referral formA chance to win one of FOUR full scholarships to the 12-week Feed The Peds® courseGrab your spot here → www.feedthepeds.com/trainingOTHER WAYS TO CONNECT & LEARN

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs enable read-through of premature stop codons to restore full-length protein production in genetic diseases. Fischer, whose daughter has Dravet syndrome, covers the company's lead programs in dilated cardiomyopathy and DMD, advantages over traditional gene therapy approaches, and the path to human proof-of-concept.

The DMD is here! And we wanna talk about all the things! Let's get it going!

The DMD is here! And we chat about what to pack to go to Austin. And we chat about Sturgis.

The DMD is here! And we are playing music from all over the place for donations of $169!

The DMD is here! And we chat about the staff's favorite OZZY and Black Sabbath songs!